Verition Fund Management
CRSP icon

Verition Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

Verition Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,900
Closed -$1.55M – 3588
2025
Q3 		$1.55M Sell
23,900
-300
-1% -$17.2K 0.01% 2180
2025
Q2 		$1.18M Buy
+24,200
New +$937K 0.01% 2352

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Verition Fund Management's CRSP Position: Q1 2026 in Review

Verition Fund Management sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 13,934 shares — an estimated $731K sold.

Verition Fund Management first reported a position in CRSP in Q4 2019 and held it in 14 quarters. The position peaked at $2.86M in Q1 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Verition Fund Management reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 13,934 CRISPR Therapeutics shares in Q1 2026, an estimated $731K.
  • Verition Fund Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 14 quarters.
  • Verition Fund Management's CRISPR Therapeutics position peaked at $2.86M in Q1 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.